ACE inhibitors and target organ protection: An expanded role for these antihypertensive agents?

Postgraduate Medicine

Volumn 116, Issue 2, 2004, Pages 11-48

  Toto, Robert D ^a   Rinner, Steven ^a   Ram, C Venkata S ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Texas Blood Pressure Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN MESYLATE; ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN POTASSIUM; METOPROLOL; MEVINOLIN; PERINDOPRIL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN; STATINE DERIVATIVE; TRANDOLAPRIL; VERAPAMIL;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL SOCIETY; META ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SMOKING; UNITED STATES;

EID: 4043094952     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2004.08.1567     Document Type: Article

References (41)

1. American Heart Association. Heart disease and stroke statistics—2004 update. Dallas: American Heart Association, 2003. Available at: http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed Jun 8, 2004
2. Lonn E, Roccaforte R, Yi Q, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002; 40 (4): 693 – 702
3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet 2000; 355 (9200): 253 – 9
4. Erratum, Lancet 2000; 356 (9232): 860
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl 1): S15 – 35
6. Mann JF, Gerstein HC, Yi Q, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42 (5): 936 – 42
7. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106 (3): 388 – 91
8. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Express. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm. Accessed Jun 8, 2004
9. National Cholesterol Education Program. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed Jun 8, 2004
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71 – 86.
11. Erratum, BMJ 2002: 324 (7330): 141
12. Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. Am J Cardiol 1995; 76 (9): 122 C-6C
13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615 – 22
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383 – 9
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7 – 22
16. Chapman JN, Kirby P, Caulfield MC, et al; Anglo-Scandinavian Cardiac Outcomes Trial. Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens 2001; 15 (Suppl 1): S23 – 6
17. Vrecer M, Turk S, Drinovec J, et al. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: metaanalysis of randomized trials. Int J Clin Pharmacol Ther 2003; 41 (12): 567 – 77
18. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000; 342 (3): 145 – 53.
19. Errata, N Engl J Med 2000; 342 (18): 1376 and 2000; 342 (10): 748
20. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 965 – 71
21. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103 (6): 904 – 12
22. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): e14 – 8
23. Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop. A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12 (12): 2832 – 7
24. Benzing T, Fleming I, Blaukat A, et al. Angiotensin-Converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99 (15): 2034 – 40
25. Lonn E, Gerstein HC, Smieja M, et al. Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. Eur Heart J 2003; 5 (Suppl E): A43 – 8
26. Lonn E, Yusuf S, Dzavik V, et al; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103 (7): 919 – 25
27. Bosch J, Yusuf S, Pogue J, et al; HOPE Investigators. Heart Outcomes Prevention Evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324 (7339): 699 – 702
28. Arnold JM, Yusuf S, Young J, et al; HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107 (9): 1284 – 90
29. Lonn E, Mathew J, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prev Rehabil 2003; 10 (6): 420 – 8
30. Bosch J, Probstfield J. Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: secondary outcomes from the HOPE trial. J Am Coll Cardiol 2003; 41 (Suppl A): 154A
31. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033 – 41.
32. Errata, Lancet 2001; 358 (9292): 1556 and 2002; 359 (9323): 2120
33. Wing LM, Reid CM, Ryan P, et al; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348 (7): 583 – 92
34. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288 (19): 2421 – 31
35. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805 – 16
36. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981 – 97.
37. Errata, JAMA 2003; 289 (2): 178 and 2004; 291 (18): 2196
38. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (10): 669 – 77
39. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670 – 6
40. Bosch J. Extended follow-up of the ramipril component of the Heart Outcomes Prevention Evaluation—The Ongoing Outcomes (HOPE-TOO). Presented at the European Society of Cardiology Congress, Aug 30-Sep 3, 2003, Vienna
41. Lamy A, Yusuf S, Pogue J, et al; Heart Outcomes Prevention Evaluation Investigators. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107 (7): 960 – 5